Skip to content
Menu

Guggenheim Maintains Buy on Genmab, Raises Price Target to $80

Benzinga Newsdesk 2 weeks ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Guggenheim analyst Michael Schmidt maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $58 to $80.

Guggenheim analyst Michael Schmidt maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $58 to $80.

Read at benzinga.com